jsterling@genengnews.com
New Rochelle, NY—Biotech and pharma companies are increasingly relying on cell-based assays in early drug discovery work, reports Genetic Engineering & Biotechnology News (GEN). The technique can provide a quick and lower cost means of testing drug candidates for toxic effects, according to an article in the April 15 issue of GEN (http://www.genengnews.com/
“Better screening technologies, noninvasive monitoring, and more automation are driving the trend toward adoption of this technology,”
More than 50% of currently marketed drugs target GPCRs, which impact a wide range of cellular processes. Multispan is looking to exploit this area and is collaborating with Promega and Molecular Devices to develop an array of applications for its GPCR cell-based assays.
Another field of much R&D interest involves protein-protein interactions. DiscoveRx created a new family of cell-based assays for the detection of protein-protein interactions using an enzyme fragment complementation assay. This system uses an enzyme acceptor, an inactive alpha-galactosidase enzyme that binds to its enzyme donor forming an active enzyme that will hydrolyze a substrate and provide a signal.
Other companies covered in the GEN article include Merck Research Laboratories, Sophion, Nanion, Novo Nordisk, ACEA Biosciences, and AstraZeneca.
For a copy of the April 15 issue of GEN, please call (914) 740-2122, or email: ebicovny@liebertpub.com
Genetic Engineering and Biotechnology News (http://www.genengnews.com), which is published 21 times a year by Mary Ann Liebert, Inc., is the most widely read biotechnology news magazine worldwide. It includes articles on Drug Discovery, Bioprocessing, OMICS, Biobusiness, and Clinical Research and Diagnostics.
